Breast Cancer

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

By October 16, 2018

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

Treatment Linked to Cognitive Scores in Breast Cancer Survivors

October 05, 2018

Researchers recruited 344 newly diagnosed non-metastatic breast cancer survivors matched with 347 cancer controls aged 60 years or older without dementia or neurological disease.

Most Breast Cancer Diagnoses Given Over the Phone

September 24, 2018

Almost 60% of participants diagnosed from 2015 to 2017 learned about their diagnosis over the telephone. Among those who heard the news in person, 40% were alone.

Case Report Describes 4 Breast CA Cases Post Organ Transplant

September 11, 2018

The authors note that with 16 months to 6 years after transplantation, the other 4 recipients developed donor-derived breast cancer, which was proven by DNA microsatellite.

Capsule Formulation of Ovarian Cancer Treatment Discontinued

By September 04, 2018

The Company has not disclosed a reason for the medication discontinuation, however in 2017, the FDA reported that olaparib capsules were being phased out of the US market.

Talazoparib Beneficial in Patients With Advanced Breast Cancer

August 16, 2018

The talazoparib group had a higher objective response rate than the standard-therapy group (62.6 vs 27.2%; odds ratio, 5.0; 95% confidence interval, 2.9 to 8.8; P<.001).

<i>TGFB1</i> Mutation Ups Radiation-Induced Breast Fibrosis Risk

August 02, 2018

The researchers found that 13.8% of patients with C-509T and 3.8% of those without the allele variant had grade 2 or higher breast fibrosis.

FDA Approves Magnetic System for Guiding Lymph Node Biopsies

July 26, 2018

In clinical testing, about 98% of patients had the same detection rate with the Sentimag System vs the control method of injecting patients with radioactive dye.

FDA Approves Additional Breast Cancer Indications for Kisqali

By July 18, 2018

In addition, Kisqali has also been approved in combination with fulvestrant to treat postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

Ready-to-Administer Gemcitabine Formulation Gets FDA Approval

By July 18, 2018

Infugem utilizes a novel technology that enables cytotoxic oncology products to be premixed in a sterile setting and to be supplied to prescribers in RTA infusion bags.

Antibody-Drug Conjugate Gets Priority Review for Metastatic Triple-Negative Breast Cancer

By July 18, 2018

The FDA has set a Prescription Drug User Fee Act date of January 18, 2019 for the treatment.

Higher Vitamin D Levels May Lower Breast Cancer Risk

July 13, 2018

When adjusting for age, body mass index, smoking status, calcium supplement intake, and study of origin, women with 25(OH)D concentrations ≥60ng/mL had an 80% lower risk of breast cancer than women with concentrations <20ng/mL (hazard ratio, 0.20; P=.03).

Mammography Use Tied to Other Preventive Tests in Older Women

July 09, 2018

The researchers found that women who underwent index screening mammography were more likely than unscreened women to later undergo Papanicolaou test (odds ratio, 1.49), bone mass measurement (odds ratio, 1.70), and influenza vaccine (odds ratio, 1.45).

Higher Rates of Cancers Observed Among Flight Attendants

June 27, 2018

Especially breast cancer, melanoma, and non-melanoma skin cancer among female flight attendants

ASCO: Endocrine Tx Noninferior for HR&#43;, HER2&#8722; Breast Cancer

June 05, 2018

The researchers found that in the analysis of invasive disease-free survival, endocrine therapy was noninferior to chemoendocrine therapy.

Personalized Therapy Promising in Metastatic Breast Cancer

June 04, 2018

The researchers found that adoptive transfer of these mutant-protein-specific tumor-infiltrating lymphocytes with interleukin-2 and checkpoint blockade mediated a reduction in cancer, with the target tumor burden reduced by 51% at the first evaluable time points 6 weeks after cell transfer.

Computer analysis is not better than human clinical evaluation when it comes to measuring breast density

May 03, 2018

Similar associations were observed with clinical BI-RADS and automated BI-RADS with respect to interval and screen-detected cancer.

Potentially Inappropriate Med Use Prevalent in Cancer Patients

April 27, 2018

Overall, 37.5% of patients with breast cancer had at least one adverse outcome; correlations included use of at least 5 medications, advanced stage, higher comorbidity, and previous emergency room visits/hospitalizations

TFs Operate Across Gene Loci Within Disease Phenotypes

April 16, 2018

"Our results nominate mechanisms that operate across risk loci within disease phenotypes, suggesting new models for disease origins," the authors write.

Endocrine Therapy-Induced Alopecia Seen in Breast Cancer

April 12, 2018

"Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents," the authors write.

Breast Cancer Diagnosis, Therapy Differ in Women With Implants

April 04, 2018

The researchers found that palpable lesions were detected at a smaller size in augmentation patients (P<0.001) and fewer lesions were detected by screening mammography in augmented patients (P=0.010)

Incidence of Breast Cancer Investigated Among Women With Schizophrenia

March 16, 2018

The researchers included 12 cohorts (760 women) in this meta-analysis. Pooled analysis showed that schizophrenia was associated with a significantly increased risk of breast cancer incidence in women (SIR, 1.31; P<0.001).

Use of Carvedilol for Anthracycline Cardiotoxicity Prevention Investigated

March 12, 2018

Carvedilol does not prevent reduction in LVEF in breast cancer but is linked to lower troponin I levels

FDA Authorizes First Direct-to-Consumer BRCA Mutation Test

By March 06, 2018

According to a National Cancer Institute study about 2% of Ashkenazi Jewish women carry 1 of the hereditary mutations the test can detect. Among other ethnic populations this occurrence is only 0% to 0.1%.

Verzenio Gains Expanded Breast Cancer Indication

By February 27, 2018

The approval of Verzenio as initial therapy in combination with an aromatase inhibitor is based on the efficacy and safety demonstrated in the pivotal MONARCH 3 clinical trial.

Kurtosis Diffusion-Weighted Imaging May Reduce False Positive Mammographies

February 23, 2018

At the predefined sensitivity of greater than 98.0%, the researchers found that the radiomics feature model reduced false-positive results from 66 to 20 in the independent test set (specificity, 70.0%); BI-RADS 4a and 4b lesions benefited from the analysis (74.0 and 60.0%, respectively).

Induced Pluripotent Stem Cells Show Promise in Preventing Tumor Growth

February 16, 2018

The iPSC vaccine inhibited melanoma recurrence at the resection site as an adjuvant and reduced metastatic tumor load, which was correlated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells.

How Strong is the Correlation Between Processed Food and Breast CA?

February 15, 2018

The researchers observed a correlation for ultra-processed food intake with increased overall cancer risk (hazard ratio for a 10% increment in the proportion of ultra-processed food in the diet, 1.12) and increased breast cancer risk (hazard ratio, 1.11)

AHA: Managing Breast CA Patients CVD Risk Requires Comprehensive Care

February 01, 2018

Current treatment for breast cancer can have a negative effect on cardiovascular health such as left ventricular dysfunction and accelerated CVD;

Investigational Metastatic Breast Cancer Tx Granted Fast Track Status

By January 25, 2018

The preliminary results found that SYD985 was well tolerated in patients previously treated with trastuzumab and ado-trastuzumab emtansine (T-DM1).